BioCryst Updates ORLADEYO Revenue Outlook and Guidance
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioCryst ( (BCRX) ) has issued an announcement.
On January 12, 2026, BioCryst Pharmaceuticals reported that preliminary, unaudited net revenue from its HAE drug ORLADEYO reached $151 million in the fourth quarter of 2025, up 22% year-on-year (36% on a comparable basis excluding prior European sales), and $601 million for full-year 2025, a 37% annual increase that surpassed its previous guidance range of $590 million to $600 million. Excluding European ORLADEYO revenue following the sale of its European business, full-year 2025 ORLADEYO revenue was $563 million, representing 43% year-on-year growth on a comparable basis, while cash, cash equivalents, restricted cash and investments stood at $338 million as of December 31, 2025; looking ahead, the company guided 2026 global ORLADEYO net revenue to $625 million–$645 million and total revenue to $635 million–$660 million, and outlined a 2026 non-GAAP operating expense range of $380 million–$390 million, rising to $450 million–$470 million including the anticipated Astria Therapeutics acquisition costs, underscoring its expectation of continued non-GAAP profitability and an expanded HAE franchise as it integrates Astria’s navenibart program and pursues further growth in rare-disease therapeutics.
The most recent analyst rating on (BCRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
BioCryst’s overall stock score reflects a mix of strong strategic moves and significant financial challenges. The positive impact of recent corporate events and earnings call guidance is offset by weak financial performance and valuation metrics. The company’s ability to address financial risks and capitalize on strategic initiatives will be crucial for future performance.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its lead product, ORLADEYO (berotralstat), is the first oral, once-daily plasma kallikrein inhibitor for prophylaxis in HAE, and the company is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics targeting a range of rare conditions.
Average Trading Volume: 5,113,779
Technical Sentiment Signal: Sell
Current Market Cap: $1.61B
See more data about BCRX stock on TipRanks’ Stock Analysis page.
